Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
(2015) In Journal of Comparative Effectiveness Research 4(5). p.447-453- Abstract
- Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month... (More)
- Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month formulations), and Euro259,000 (EU5) and Euro300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8201713
- author
- Merseburger, Axel S. ; Björk, Thomas LU ; Whitehouse, James and Meani, Davide
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- costs, economics, leuprorelin, luteinizing hormone-releasing hormone, agonists, prostate cancer
- in
- Journal of Comparative Effectiveness Research
- volume
- 4
- issue
- 5
- pages
- 447 - 453
- publisher
- Future Medicine Ltd.
- external identifiers
-
- wos:000363397600003
- scopus:84945321592
- pmid:25521079
- ISSN
- 2042-6305
- DOI
- 10.2217/cer.14.82
- language
- English
- LU publication?
- yes
- id
- 41374421-0476-4e7a-85a1-5e8720ae1290 (old id 8201713)
- date added to LUP
- 2016-04-01 14:56:32
- date last changed
- 2022-04-30 05:15:08
@article{41374421-0476-4e7a-85a1-5e8720ae1290, abstract = {{Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month formulations), and Euro259,000 (EU5) and Euro300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.}}, author = {{Merseburger, Axel S. and Björk, Thomas and Whitehouse, James and Meani, Davide}}, issn = {{2042-6305}}, keywords = {{costs; economics; leuprorelin; luteinizing hormone-releasing hormone; agonists; prostate cancer}}, language = {{eng}}, number = {{5}}, pages = {{447--453}}, publisher = {{Future Medicine Ltd.}}, series = {{Journal of Comparative Effectiveness Research}}, title = {{Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations}}, url = {{http://dx.doi.org/10.2217/cer.14.82}}, doi = {{10.2217/cer.14.82}}, volume = {{4}}, year = {{2015}}, }